Chartwell Retirement Residences

Senior Housing Demand Will Build Sustained Market Leadership

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

29 Dec 24

Updated

10 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

26.8%

7D

-0.5%

Loading

1Y

26.8%

7D

-0.5%

You can edit this narrative until Dec 11 7:05 PM. Then, changes will post as Updates.

Author's Valuation

CA$22.9513.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 10 Dec 25

Fair value Increased 0.22%

CSH.UN: New Buy Rating And Equity Raise Will Drive Shares Higher

Analysts have modestly raised their price target on Chartwell Retirement Residences to about C$22.95 from C$22.90. They cited stronger revenue growth expectations that more than offset slightly lower margin forecasts, supported by recent target increases and new Buy-rated coverage on the stock.

Shared on 26 Nov 25

Fair value Increased 3.57%

CSH.UN: Coverage Initiation and Investor Day Will Drive Shares Higher

Analysts have raised their price target for Chartwell Retirement Residences from approximately C$22.11 to C$22.90, reflecting confidence in the company's improving profit margin and strong expected revenue growth. Analyst Commentary Bullish Takeaways Bullish analysts highlight recent price target increases, reflecting growing confidence in Chartwell Retirement Residences' outlook and operational progress.

Shared on 10 Nov 25

Fair value Increased 2.31%

CSH.UN: Upcoming Coverage Initiation Will Likely Drive Earnings Upside

Analysts have raised their price target for Chartwell Retirement Residences from $21.61 to $22.11 per share. They cite improved profit margin forecasts and a new Buy rating from recent coverage initiation as reasons for the change.

Shared on 04 Sep 25

As both Chartwell Retirement Residences’ future P/E and net profit margin remained essentially unchanged, analysts have maintained their fair value estimate, with the consensus price target steady at CA$21.61. What's in the News Acquired Les Tours Angrignon in Montreal for $88.5 million, a 449-suite complex to be upgraded for alignment with Chartwell's standards; closing expected late Q3 2025.

Shared on 01 May 25

Fair value Increased 25%

Shared on 23 Apr 25

Fair value Decreased 16%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on 17 Apr 25

Fair value Increased 1.78%

AnalystConsensusTarget has decreased profit margin from 7.7% to 6.2% and increased future PE multiple from 77.3x to 98.3x.

Shared on 09 Apr 25

Fair value Increased 0.70%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 0.63%

AnalystConsensusTarget has increased future PE multiple from 71.0x to 79.0x.

Shared on 19 Mar 25

Fair value Decreased 6.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

AnalystConsensusTarget Fair Value

CA$22.95

13.3% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

13.52%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.12%

Calculation

CA$130.31m

Earnings '28

x

78.29x

PE Ratio '28

=

CA$10.20b

Market Cap '28

CA$10.20b

Market Cap '28

/

372.35m

No. shares '28

=

CA$27.40

Share Price '28

CA$27.40 Share Price '28

Discounted to 2025 @ 6.12% p.a.

=

CA$22.93

Fair Value '25